Serum magnesium concentration is independently associated with non‐alcoholic fatty liver and non‐alcoholic steatohepatitis

Background The pathogenesis of non‐alcoholic fatty liver disease (NAFLD) has not been well recognized yet. Objective This study aimed to investigate the association between serum magnesium concentration and NAFLD. Methods Study participants were healthy individuals who had undergone liver biopsies between January 2012 and August 2015 as a routine pre‐transplant check‐up before living donor liver transplantation. Liver biopsy specimens were evaluated by an expert pathologist regarding presence of hepatic steatosis and steatohepatitis. Serum magnesium concentration was measured and compared in those with normal liver biopsy and those with steatosis and steatohepatitis. Results A total of 226 individuals were included. Eighty‐two individuals (36.2%) had hepatic steatosis and 22 (9.7%) individuals had steatohepatitis and steatosis in their liver histology. Lower serum magnesium concentration was independently associated with hepatic steatosis (OR: 0.059; 95% CI: 0.011–0.325, p  = 0.001). Serum magnesium concentration was independently associated with steatohepatitis compared to those without steatohepatitis (1.80 ± 0.48 mg/dl and 2.18 ± 0.31 mg/dl) (OR: 0.11; 95% CI: 0.02–0.41, p  = 0.001). Serum magnesium concentration was significantly lower in individuals with steatohepatitis (1.80 ± 0.48 mg/dl) compared to individuals without steatosis (2.23 ± 0.31 mg/dl, p  < 0.001) and individuals with only steatosis (2.07 ± 0.29 mg/dl, p  = 0.017). Conclusion Serum magnesium concentration is independently associated with hepatic steatosis and steatohepatitis in our study population.